Skip to content

SFA for Pharma

Pharmaceutical field sales operates under constraints that most other industries don’t face. Regulatory compliance, sample management, doctor relationship tracking, and chemist coverage all require SFA capabilities that go well beyond basic order capture.

The productivity opportunity is real. Clarivate’s survey of physicians found that doctors average just 11 minutes per pharma rep visit - and the average rep visits only 3 doctors per day, with 10–15 minutes of wait time per visit plus significant commute between clinics. That means a large portion of an MR’s working day is unproductive travel and waiting. SFA is the infrastructure that reclaims it.

A typical pharma field sales operation has two distinct tracks that SFA must support simultaneously:

Medical Rep (MR) → Doctor calls

  • Scheduled visits to doctors, specialists, and hospitals
  • Sample distribution with sign-off and compliance tracking
  • Detailing sessions presenting clinical data
  • Relationship management over a long prescribing cycle

MR → Chemist/Pharmacy coverage

  • Ensuring product availability at chemists near target doctors
  • Checking prescription fulfilment rates
  • Capturing secondary sales data
  • Managing stockouts and near-expiry products

Most pharma SFA implementations fail because they try to handle both tracks with a single workflow designed for only one of them.

In pharma, compliance shapes every SFA requirement.

Sample distribution is heavily regulated in most markets. SFA must:

  • Track sample inventory issued to each rep at the beginning of the period
  • Record sample hand-offs with doctor signature (digital or physical)
  • Generate sample reconciliation reports (issued vs. distributed vs. remaining)
  • Flag discrepancies for manager review
  • Maintain an audit trail for regulatory inspection

A rep who cannot account for samples is a compliance liability. SFA that handles sample management properly is not a nice-to-have in pharma - it is mandatory.

Every doctor visit must be documented. Research by Clarivate found physicians average just 11 minutes per rep interaction - which means call reports that take more than 2 minutes to complete will be filled in retrospectively and inaccurately. SFA design matters: the form should be fast, structured, and require minimal free-text typing.

SFA should capture:

  • Doctor visited (from pre-defined list or new additions)
  • Products detailed (which brands discussed)
  • Samples left (quantity and batch number)
  • Doctor feedback and objections
  • Next call objectives

Different products target different doctor specialties. SFA should allow managers to track:

  • Which specialties are being covered vs. target coverage
  • Which doctors in each specialty are being visited at target frequency
  • Which doctors have lapsed (not visited in 60+ days)

The doctor database is the pharma equivalent of the FMCG outlet universe. Fierce Healthcare surveys show 31% of physician practices are never visited by pharma reps - meaning significant commercial opportunity is being left unaddressed simply because it’s not mapped in the system.

A clean doctor database in SFA includes:

  • Specialties and sub-specialties: not all cardiologists are the same target
  • Prescription potential: high, medium, low prescribers of your category
  • Hospital affiliations: which hospitals a doctor is attached to
  • Visit frequency targets: A doctors monthly, B doctors bi-monthly, C doctors quarterly
  • Contact preferences: some doctors only see reps on specific days

Doctor data goes stale fast. Doctors relocate, retire, change specialties, or switch hospitals. SFA should have a process for reps to flag changes, and someone must own keeping the database current.

The chemist layer is where prescriptions become sales. Fierce Healthcare research shows that nearly 50% of multi-physician practices receive pharma rep visits every week - but if product isn’t available at the chemists near those doctors, the detailing investment is wasted.

SFA should enable:

  • Chemist universe management: all chemists near target doctors, with tier classification
  • Stock availability checks: rep confirms product is on shelf during the visit
  • Near-expiry tracking: rep records products close to expiry for return or replacement
  • Prescription fill rate: tracking how many prescriptions written by target doctors are being filled at covered chemists
KPIWhat It Measures
Doctor coverage% of target doctors visited in the period
Call averageAverage doctor calls per rep per day
Coverage quality% of A-class doctors visited at target frequency
Sample compliance% of sample distributions with complete sign-off
Chemist availability% of chemists with product in stock
Lapsed doctors% of target doctors not visited in 60+ days
New doctor additionsDoctors added to universe by reps in the field

Pharma territory design is different from FMCG. Reps don’t follow fixed routes - they work around doctor availability, clinic hours, and hospital visiting schedules.

SFA should support:

  • Flexible daily planning: rep plans the day based on doctor availability, not a fixed sequence
  • Call scheduling: ability to book doctor visits in advance and receive reminders
  • Hospital visit tracking: separate workflow for hospital calls (multiple doctors in one building)
  • Joint field work: when a manager accompanies a rep, both activities are logged

Replicating paper call reports digitally. Most pharma companies have 2-page paper call reports designed for administrative compliance, not operational insight. Moving these forms into SFA verbatim creates a slow, painful workflow. Redesign the call report for speed first, compliance second.

Ignoring the chemist layer. Many pharma SFA implementations focus entirely on doctor detailing and skip chemist coverage tracking. This creates a blind spot: you know which doctors were visited, but not whether the prescriptions written are being filled.

Not integrating with stockist/distributor data. Pharma distribution goes company → stockist → chemist. Without stockist integration, you have no visibility into whether product is available when chemists need to fill prescriptions.

Treating all doctors equally. A doctor who writes 50 prescriptions per month for your category and a doctor who writes 2 need different call frequencies, different sample quantities, and different detailing approaches. SFA that doesn’t support doctor tiering results in reps optimising for visit counts rather than business impact.

One underutilised benefit of pharma SFA: the data it generates is exactly what regulators ask for.

Sample distribution audits, doctor call records, and rep activity logs are typically required for pharma compliance in most markets. Companies that run SFA well can generate regulatory reports in hours. Companies that don’t recreate data from memory and paper when inspections happen.

This is a strong internal argument for SFA investment in pharma: it’s not just a sales productivity tool - it’s your compliance infrastructure.